Free Trial
NASDAQ:ACET

Adicet Bio Q1 2025 Earnings Report

Adicet Bio logo
$0.72 +0.11 (+18.05%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$0.73 +0.01 (+0.97%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adicet Bio EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.34
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Adicet Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adicet Bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Adicet Bio's Q2 2025 earnings is scheduled for Tuesday, May 13, 2025

Adicet Bio Earnings Headlines

Wedbush Has Bullish Forecast for Adicet Bio Q3 Earnings
Elon Warns “America Is Broke”. Trump’s Plan Inside.
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
See More Adicet Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adicet Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adicet Bio and other key companies, straight to your email.

About Adicet Bio

Adicet Bio (NASDAQ:ACET), a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

View Adicet Bio Profile

More Earnings Resources from MarketBeat